unknown
Stage
About
Melodia Therapeutics is a Basel-based biotechnology company developing therapies for neutrophil-driven diseases. The company is advancing a cathepsin-C inhibitor program and has entered licensing collaborations to develop these therapeutic candidates.
Explore Melodia Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.